ArticleOncotarget2016

pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.

Jun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.